



RECEIVED

JUL 03 2001

TECH CENTER 1600/2900
H4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Lee, K-F., et al.

ART UNIT: 1632 7-9-01 P.2.

FILED: November 16, 2000

EXAMINER: Ton, T.

SERIAL NO.: 09/714,692

DOCKET: D6233CIP

FOR: Corticotropin Releasing Factor
Receptor 2 Deficient Mice and
Uses Thereof

The Assistant Commissioner of Patents and Trademarks
BOX NON-FEE AMENDMENT
Washington, DC 20231

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

Responsive to the Restriction requirement mailed April 6, 2001 in the above-referenced patent application, Applicants hereby elect Invention VIII, claims 20-23, drawn to protein therapy to inhibit angiogenesis, without traverse.

This is intended to be a complete response to the Office Action mailed April 6, 2001. If any issues remain outstanding, the Examiner is respectfully requested to telephone the undersigned

attorney of record for immediate resolution. Should any additional fees be due, please debit Deposit Account 07-1185.

Respectfully submitted,

Date: June 25, 2001



Benjamin Aaron Adler, Ph.D.,J.D.
Counsel for Applicant
Registration No. 35,423

Adler & Associates
8011 Candle Lane
Houston, Texas 77071
(713) 270-5391
badler1@houston.rr.com